1. Scrip
  2. >>Business
  3. >>Financing

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

First Financing Since $20m Seed Round In 2021

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

HAYA is searching the dark genome for long non-coding RNA targets (Shutterstock)

HAYA Therapeutics formed around co-founder and CEO Samir Ounzain’s discovery of a long non-coding RNA (lncRNA) known as Wisper, associated with fibrosis in the heart, and developed a platform to search the dark genome for lncRNAs that could be targeted to treat the root cause of common and chronic diseases. Four years after raising its seed round and seven months after entering into a collaboration with Eli Lilly, the company closed a $65m series A round.

Key Takeaways
  • HAYA raised $65m in series A venture capital to take its lead asset, HTX-001 for nHCM, into the clinic. The start-up advanced its lncRNA-targeting platform to this point with $20m in seed funding.

Lausanne, Switzerland-based HAYA, which keeps a US base in San Diego, announced the new funding on 8 May – its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.

Cash Bonanza For European Oncology-Based Biotechs

 
• By Kevin Grogan

Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

 
• By Anju Ghangurde

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

Kailera’s $600m Mega-Raise Signals Obesity Boom Is Not Slowing Down

 
• By Manas Mishra and Sushmita Panda

Kailera has chalked up its second massive fund raise in the space of a year as it seeks to begin a global trial of its dual GLP-1/GIP receptor agonist by the end of the year.

More from Scrip

Sponsored by :

Podcast: Innovating Autoimmune Treatment with In Vivo CAR-T

As in vivo CAR-T therapy nears clinical use, researchers and industry leaders explore how it could transform autoimmune disease treatment. Novotech’s Pete Robinson joins Citeline’s Meredith Landry to discuss the science, strategy, and partnerships shaping the future of cell therapy.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.